500 Global and Ashdod Port Company Unveil Batch 1 of the Ashdod Accelerator by 500
13.6.2022 11:00:00 EEST | Business Wire | Press release
500 Global, a leading global venture capital firm, and Ashdod Port Company (“Ashdod Port”), the national port of Israel, unveiled today 12 startups in Batch 1 of the Ashdod Port Accelerator by 500. They hail from Israel, with one startup based in Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220612005046/en/
500 Global and Ashdod Port Company partnered in January 2022 to mentor startups and help them test and validate partnership opportunities with Ashdod Port. The Ashdod Port Accelerator by 500 program consisted of 12 weeks of masterclasses and dedicated coaching in areas such as business strategy, sales & marketing, and fundraising from 500 Global’s network of expert mentors. The program is followed by participation in an accelerated proof-of-concept for five to six months, with the potential for investment by Ashdod Port.
Program graduates in this first cohort are addressing solutions to issues in energy, logistics, seaport operations, and shipping. They will continue to work on their proof-of-concept at Ashdod Port through October, with the help of trained port personnel. On June 22, 2022, they will present their initiatives in Ashdod at the Blue Ocean for Startups event, which will also be streamed via webcast to a curated audience of industry leaders and ecosystem players.
This exclusive event features a panel of industry experts who will share insights into the role of startups in shaping innovation, as well as trends and investment opportunities in the maritime sector in Israel and around the world.
“Ashdod Port, The Port of Israel, is proud to be a leader in the innovation industry, providing beta sites for startups and supporting new technologies in the maritime sector. With a goal of being not only the biggest, but also the smartest port in Israel, Ashdod Port has set itself a goal to support innovation. We're proud of our relationship with 500 Global, and to offer one of the only accelerator programs that runs in a port. There is no doubt that the port will become a major player in the ecosystem soon. We are happy to host our Demo Day here at the port on June 22nd, and present to you how, in a short period of time, the program developed momentum and was able to promote the startups in a variety of ways–thanks to the program and the people from the port who accompany them,” said Roy Avrahami, CIO of Ashdod Port.
“Our Ashdod Port Accelerator by 500 is a truly unique initiative, thanks to our partner’s vision and belief that technology can play a central role in modernizing the maritime industry. As a result, Ashdod stands to serve as a model for other ports. Our first batch of startups has gained a solid foundation of corporate partnerships by working with Ashdod Port, and we believe they’re set up for success in Israel and beyond,” said Ee Ling Lim, Executive Director of Global Programs at 500 Global.
"The partnership between 500 Global and Ashdod Port is a groundbreaking collaboration to strengthen the port as a key player in the Israeli innovation ecosystem. The goal of the Ashdod Port Accelerator by 500 is to create a new generation of startups that are able to address the port’s pain points and also be attractive enough to be implemented in other ports around the world. In light of this unique partnership, we look forward to supporting and participating in the upcoming Demo Day that will take place on June 22, 2022,” said Tal Chen, Partner at Deloitte Israel, and Co-Leader of Deloitte Catalyst.
To attend the Blue Ocean for Startups event, please sign up here. Learn more about the event and startups presenting here.
About 500 Global
500 Global is a venture capital firm with $2.7B in assets under management that invests early in founders building fast-growing technology companies. We focus on markets where technology, innovation, and capital can unlock long-term value and drive economic growth. We work closely with key stakeholders and advise governments and corporations on how best to support entrepreneurial ecosystems so startups can thrive. 500 Global has backed over 5,000 founders representing more than 2,600 companies operating in 81 countries. Our portfolio includes 45 companies valued at over $1 billion and 130+ companies valued at over $100 million. Our 140+ plus team members are located in more than 20 countries and bring experience as entrepreneurs, investors, and operators from some of the world’s leading technology companies.
About Ashdod Port
Ashdod Port, The Port of Israel, is the leading seaport of the State of Israel with a strategically advantageous location. Experiencing growing demand, Ashdod Port has incorporated technological advancements into its operations and has inspired other ports around the world. Ashdod Port has collaborated with other institutions and ports to establish innovation embassies that promote growth within the industry. It frequently invests in new equipment and infrastructure for private and public benefit, and supports promising early stage entrepreneurs to bolster the maritime innovation ecosystem in Israel and globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220612005046/en/
Contact information
Felicia Chiriac
Redhill
felicia.chiriac@redhill.asia
+6596445927
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
